Abstract:Background: Atherosclerosis is a chronic inflammatory disorder whose development is inversely correlated with high-density lipoprotein concentration. Current therapies involve pharmaceuticals that significantly elevate plasma high-density lipoprotein cholesterol concentrations. Our studies were conducted to investigate the effects of low-dose lipid-free apolipoprotein A-I (apoA-I) on chronic inflammation. The aims of these studies were to determine how subcutaneously injected lipid-free apoA-I reduces accumulation of lipid and immune cells within the aortic root of hypercholesterolemic mice without sustained elevations in plasma high-density lipoprotein cholesterol concentrations. Methods and results: Ldlr-/- and Ldlr-/- apoA-I-/- mice were fed a Western diet for a total of 12 weeks. After 6 weeks, a subset of mice from each group received subcutaneous injections of 200 μg of lipid-free human apoA-I 3 times a week, while the other subset received 200 μg of albumin, as a control. Mice treated with lipid-free apoA-I showed a decrease in cholesterol deposition and immune cell retention in the aortic root compared with albumin-treated mice, regardless of genotype. This reduction in atherosclerosis appeared to be directly related to a decrease in the number of CD131 expressing cells and the esterified cholesterol to total cholesterol content in several immune cell compartments. In addition, apoA-I treatment altered microdomain cholesterol composition that shifted CD131, the common β subunit of the interleukin 3 receptor, from lipid raft to nonraft fractions of the plasma membrane. Conclusions: ApoA-I treatment reduced lipid and immune cell accumulation within the aortic root by systemically reducing microdomain cholesterol content in immune cells. These data suggest that lipid-free apoA-I mediates beneficial effects through attenuation of immune cell lipid raft cholesterol content, which affects numerous types of signal transduction pathways that rely on microdomain integrity for assembly and activation.

Aspirin increases apolipoprotein-A-I-mediated cholesterol efflux via enhancing expression of ATP-binding cassette transporter A1.

Ascorbic Acid Enhances Low-Density Lipoprotein Receptor Expression by Suppressing Proprotein Convertase Subtilisin/kexin 9 Expression.

Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis Through Regulation of the PPARδ-AMPK-PGC-1αPathway in Dyslipidemic Conditions

Activation of Activator Protein 2 Alpha by Aspirin Alleviates Atherosclerotic Plaque Growth and Instabilityin Vivo

Aspirin Suppresses NFκB1 Expression and Inactivates Camp Signaling Pathway to Treat Atherosclerosis.

Effect of simvastatin on cholesterol efflux and expression of ABCA1 and CD36 in THP-1 macrophages

Effects of apolipoproteinA1 on reverse cholesterol transport and expression of ATP-binding cassette transporter A1 in human acute monocytic leukemia cell line macrophage-derived foam cells

Apelin-13 Increases Expression of ATP-binding Cassette Transporter A1 Via Activating Protein Kinase C Α Signaling in THP-1 Macrophage-Derived Foam Cells.

Aspirin Inhibits MMP-2 and MMP-9 Expressions and Activities through Upregulation of PPARα/γ and TIMP Gene Expressions in ox-LDL-Stimulated Macrophages Derived from Human Monocytes

Aspirin Protects Human Coronary Artery Endothelial Cells by Inducing Autophagy

Aspirin ameliorates atherosclerotic immuno-inflammation through regulating the Treg/Th17 axis and CD39-CD73 adenosine signaling via remodeling the gut microbiota in ApoE-/- mice

Effect of astragalus polysaccharides on cholesterol efflux in THP-1 macrophage-derived foam cells

Targeted inhibition of ATP-binding cassette transporter A1 protein degradation promotes reverse cholesterol transport and reduces atherosclerosis in mice (832.15)

Intermedin Ameliorates Atherosclerosis by Increasing Cholesterol Efflux Through the Camp-Pka Pathway in Macrophage RAW264.7 Cell Line

Effect of ox-LDL on the expression of ATP-binding cassette transporter A1 in monocyte of patients with coronary heart disease

Effect of S-aspirin, a Novel Hydrogen-Sulfide-releasing Aspirin (ACS14), on Atherosclerosis in Apoe-Deficient Mice

Lipid-Free Apolipoprotein A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio

Eicosapentaenoic Acid Reduces ABCA1 Serine Phosphorylation and Impairs ABCA1-dependent Cholesterol Efflux Through Cyclic AMP/protein Kinase A Signaling Pathway in THP-1 Macrophage-Derived Foam Cells.

Chronic Application of Low-Dose Aspirin Affects Multiple Parameters of Three Blood Cellular Types and Antithrombin Activity: A 1:1:1 Propensity Score Matching Analysis

[Effects of Oxidized Low-Density Lipoprotein on Cholesterol Efflux in 3T3-L1 Cells].

Influence of Apolipoprotein A-I on Expression of Monocyte Chemoattractant Protein-1, Vascular Celladhesion Molecule-1 and ATP-binding Cassette Transporter A1 in Macrophage Derived Foam Cells